Results 231 to 240 of about 109,968 (264)

Chimeric Antigen Receptor T-Cell Immunotherapy for Cancer

Proceedings of the Fourth International Conference on Biological Information and Biomedical Engineering, 2020
Cancer is a disease which causes a high death rate each year. The traditional therapies for treating cancers, for example, radiotherapy and chemotherapy, can cause the damage effect on both cancer cells and normal cells. Therefore, new immune therapies, Chimeric Antigen Receptor T-Cell (CAR-T cell) immunotherapy which can recognize the receptor on the ...
openaire   +1 more source

Chimeric antigen receptor T-cell therapies for lymphoma

Nature Reviews Clinical Oncology, 2017
New therapies are needed for patients with Hodgkin or non-Hodgkin lymphomas that are resistant to standard therapies. Indeed, unresponsiveness to standard chemotherapy and relapse after autologous stem-cell transplantation are indicators of an especially poor prognosis.
Jennifer N, Brudno, James N, Kochenderfer   +1 more
openaire   +2 more sources

The road ahead for chimeric antigen receptor T cells

The Journal of Immunology
Abstract Chimeric antigen receptor T (CART) cell therapy is an innovative form of immunotherapy that has shown remarkable and long-term responses in patients with B-cell malignancies. Over the years, the field has made significant progress in our understanding of the successes and challenges associated with CART cell therapy.
Carli M, Stewart, Elizabeth L, Siegler, Saad S, Kenderian   +2 more
openaire   +2 more sources

Imaging of T Cells Expressing Chimeric Antigen Receptors

Immunotherapy, 2011
1411 ISSN 1750-743X Immunotherapy (2011) 3(12), 1411–1414 10.2217/IMT.11.138 © 2011 Future Medicine Ltd “Macroscopic imaging, exemplified by bioluminescent imaging, PET and MRI has been useful for establishing the trafficking pattern of adoptively transferred chimeric antigen receptor (CAR)+ T cells, their persistence and antitumor activity ...
Janos, Roszik, Brian, Rabinovich, Laurence J N, Cooper   +2 more
openaire   +2 more sources

Immunogenicity of Chimeric Antigen Receptor T-Cell Therapeutics

BioDrugs, 2019
Chimeric antigen receptor (CAR) T-cell immunotherapy has gained significant attention in the past decade due to its considerable potential in the treatment of various types of malignancies, particularly hematological. While success has been achieved in a number of studies, and two CAR-T-cell products were recently approved by the US Food and Drug ...
Boris Gorovits, Eugen Koren
openaire   +2 more sources

Barriers to Chimeric Antigen Receptor T-Cell Therapy

JAMA Oncology
This cohort study examines barriers to access of CAR T-cell therapy among patients with hematologic cancer referred for this treatment.
Yannis K, Valtis, Kuo-Kai, Chin, David, Nemirovsky, Sean M, Devlin, Meira, Yisraeli Salman, Leora, Boussi, Briana, Cadzin, Carina, McLoughlin, Elizabeth, Cathcart, Paul, Davis, Chelsea, Brooklyn, Todd, Goldstein, Chris, Famulare, Gunjan L, Shah, Moneeza, Walji, Michael, Scordo, Alexander P, Boardman, Roni, Shouval, Eytan M, Stein, Mark B, Geyer, Sham, Mailankody, M Lia, Palomba, Saad Z, Usmani, Gilles, Salles, Sergio A, Giralt, Miguel-Angel, Perales, Jae H, Park   +26 more
openaire   +2 more sources

Complications of Chimeric Antigen Receptor T-cell Therapy

Emergency Medicine Clinics of North America
Chimeric antigen receptor T-cell therapy is a modern approach in our treatment of cancer. However, it is not without potential side effects. While cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome are some of the more well-known toxicities, other potential complications include B- and T-cell aplasia ...
Gregory, Chang, Brian, Cameron
openaire   +2 more sources

Chimeric Antigen Receptor T Cells in Myeloma

New England Journal of Medicine, 2016
Alfred L, Garfall, Edward A, Stadtmauer, Carl H, June   +2 more
openaire   +3 more sources

Chimeric antigen receptor T cells for ALL

The Lancet, 2015
Persis J, Amrolia, Martin, Pule
openaire   +2 more sources

Critical care management of chimeric antigen receptor T‐cell therapy recipients

Ca-A Cancer Journal for Clinicians, 2022
Alexander Shimabukuro-Vornhagen, Boris Böll, Peter Schellongowski   +2 more
exaly